Introduction
Brazil is presently (2010) the second largest producer of GM crops. However, until 2005 there was a lack of legal framework to support both research activities and the commercial release of GMOs. This scenario has radically changed in 2005, by the decree of law nr. 11.105. Nicknamed Biosafety Law, it provides for safety norms and inspection mechanisms for the construction, culture, production, manipulation, transportation, transfer, import, export, storage, research, marketing, environmental release and discharge of genetically modified organisms -GMOs and their by-products, among other measures.
After the indispensable risk analysis, a GM plant can be approved for commercial release. In May 2010 a query at the CERA database returned 21 results for Brazil, corresponding to different events in soybean (6), cotton (8) and maize (9). Single and stacked events tolerant to herbicides or insect-resistant are presently been planted for all three crops. If, for each single event and for the stacks, a laborious post market monitoring plan were to be executed, the total costs would be unbearably high.
The applicant, i.e. the seed company in the case of the three common crops, is legally responsible for the monitoring in Brazil. It is also responsible to produce an adequate monitoring plan. Since the rules in Annex I are far from being clear, the applicants either propose an elaborated plan for case-specific monitoring or, conversely, submit a very simple plan, targeting some potential adverse effect that can be more easily evaluated in commercial fields. All data generated must be reported to federal agencies belonging to at least three different ministries.
ANNEX I (abbreviated by the authors)

POST-MARKET MONITORING
1. An applicant shall submit a post-market monitoring plan.
2. The applicant shall submit the monitoring plan upon delivering the application for commercial release and shall have a term of thirty (30) days to adapt its proposed monitoring plan.
3. The monitoring shall be conducted by the applicant with the purpose of oversee the effects resulting from commercial release of a GMO and its derivatives to the environment and human and animal health.
(4 and 5 not relevant here)
6. Once approved, the monitoring plan shall be distributed to supervisory agencies and entities for their knowledge and follow-up.
7. Applicant shall submit an yearly monitoring report during a period of at least five (5) years of commercial release and a final report at the completion of such monitoring term, such reports to be delivered to supervisory agencies.
Legal framework 2: the Biosafety Law
Monitoring is also a responsibility of some federal agencies, CTNBio is aware of these challenges and has already started to adjust the NR-5 to better guide the applicants in their writing of monitoring plans.
